Covariate-adaptive randomization represents an advanced methodology in the design of clinical trials, ensuring a balanced distribution of prognostic factors among treatment groups. This approach ...

DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study. Background: GBM AGILE (Glioblastoma Adaptive, Global, ...

Response-adaptive designs allow the randomization probabilities to change during the course of a trial based on cumulated response data so that a greater proportion of patients can be allocated to the ...

An innovative phase 2 clinical trial designed to find new potential treatments for glioblastoma has reported initial results. While none of the three therapeutics tested so far improved overall ...